跳至主要内容

Cholangiocarcinoma in Patients with Crohn’s Disease

Read full paper at:
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=52687#.VKC_4cCAM4

Cholangiocarcinoma is an uncommon malignancy that increases with age. Cholangiocarcinoma has been linked to inflammatory bowel disease, and a relationship between inflammatory bowel disease, anti-tumour necrosis factor alpha antibody (Infliximab) and cholangiocarcinoma has been suggested. Although cholangiocarcinoma is usually associated with ulcerative colitis, recently more cases are being seen in association with Crohn’s disease. The risk of cancer in patients treated with Infliximab has been discussed, and whether Infliximab is associated with an increased risk of cholangiocarcinoma is not clear. Cholangiocarcinoma is an uncommon malignancy and it is difficult to establish a clear correlation with Infliximab treatment. A large number of reports are needed to further address these issues. 
Cite this paper
Debs, T. , Reccia, I. , El-Hajj, I. and El-Rassi, Z. (2015) Cholangiocarcinoma in Patients with Crohn’s Disease. Journal of Cancer Therapy, 6, 21-24. doi: 10.4236/jct.2015.61003. 
 

[1] Bragazzi, M.C., Cardinale, V., Carpino, G., Venere, R., Semeraro, R., Gentile, R., Gaudio, E. and Alvaro, D. (2012) Cholangiocarcinoma: Epidemiology and Risk Factors. Translational Gastrointestinal Cancer, 1, 21-32.
[2] Blechacz, B., Komuta, M., Roskams, T., Gores, G.J., et al. (2011) Clinical Diagnosis and Staging of Cholangiocarcinoma. Nature Reviews Gastroenterology & Hepatology, 8, 512-522.
http://dx.doi.org/10.1038/nrgastro.2011.131
[3] Patel, T. (2011) Cholangiocarcinoma—Controversies and Challenges. Nature Reviews Gastroenterology & Hepatology, 8, 189-200. http://dx.doi.org/10.1038/nrgastro.2011.20
[4] Carriaga, M.T. and Henson, D.E. (1995) Liver, Gallbladder, Extrahepatic Bile Ducts, and Pancreas. Cancer, 75, 171-190.
http://dx.doi.org/10.1002/1097-0142(19950101)75:1+<171::AID-CNCR2820751306>3.0.CO;2-2
[5] Shaib, Y.H. and El-Serag, H.B. (2004) The Epidemiology of Cholangiocarcinoma. Seminars in Liver Disease, 24, 115-125. http://dx.doi.org/10.1055/s-2004-828889
[6] Schnitzler, F., Fidder, H., Ferrante, M., Noman, M., Arijs, I., Van Assche, G., Hoffman, I., Van Steen, K., Vermeire, S. and Rutgeerts, P. (2009) Long-Term Outcome of Treatment with Infliximab in 614 Patients with Crohn’s Disease: Results from a Single-Centre Cohort. Gut, 58, 492-500.
http://dx.doi.org/10.1136/gut.2008.155812
[7] O’Donnell, S., Murphy, S., Anwar, M.M., O’Sullivan, M., Breslin, N., O’Connor, H.J., Ryan, B.M. and O’Morain, C.A. (2011) Safety of Infliximab in 10 Years of Clinical Practice. European Journal of Gastroenterology & Hepatology, 23, 603-606. http://dx.doi.org/10.1097/MEG.0b013e3283479125
[8] Hudesman, D., Lichtiger, S. and Sands, B. (2013) Risk of Extraintestinal Solid Cancer with Anti-TNF Therapy in Adults with Inflammatory Bowel Disease: Review of the Literature. Inflammatory Bowel Diseases, 19, 644-649. http://dx.doi.org/10.1097/MIB.0b013e318280ebbd
[9] Lust, M. and Travis, S. (2009) Is Anti-TNF Therapy Always Prohibited in Patients with Inflammatory Bowel Disease and Previous Malignancy? Practical Gastroenterology. Inflammatory Bowel Disease.
[10] Rojas-Feria, M., Castro, M., Suárez, E., Ampuero, J. and Romero-Gómez, M. (2013) Hepatobiliary Manifestations in Inflammatory Bowel Disease: The Gut, the Drugs and the Liver. World Journal of Gastroenterology, 19, 7327-7340. http://dx.doi.org/10.3748/wjg.v19.i42.7327
[11] Pedersen, N., Duricova, D., Elkjaer, M., Gamborg, M., Munkholm, P. and Jess, T. (2010) Risk of Extra-Intestinal Cancer in Inflammatory Bowel Disease: Meta-Analysis of Population-Based Cohort Studies. American Journal of Gastroenterology, 105, 1480-1487. http://dx.doi.org/10.1038/ajg.2009.760
[12] Erichsen, R., Jepsen, P., Vilstrup, H., Ekbom, A. and S?rensen, H.T. (2009) Incidence and Prognosis of Cholangiocarcinoma in Danish Patients with and without Inflammatory Bowel Disease: A National Cohort Study, 1978-2003. European Journal of Epidemiology, 24, 513-520. http://dx.doi.org/10.1007/s10654-009-9365-4
[13] Biancone, L., Orlando, A., Kohn, A., Colombo, E., Sostegni, R., Angelucci, E., Rizzello, F., Castiglione, F., Benazzato, L., Papi, C., Meucci, G., Riegler, G., Petruzziello, C., Mocciaro, F., Geremia, A., Calabrese, E., Cottone, M. and Pallone, F. (2006) Infliximab and Newly Diagnosed Neoplasia in Crohn’s Disease: A Multicentre Matched Pair Study. Gut, 55, 228-233. http://dx.doi.org/10.1136/gut.2005.075937
[14] Berman, M.D., Falchuk, K.R. and Trey, C. (1980) Carcinoma of the Biliary Tree Complicating Crohn’s Disease. Digestive Diseases and Sciences, 25, 795-797. http://dx.doi.org/10.1007/BF01345302
[15] Krause, J.R., Ayuyang, H.Q. and Ellis, L.D. (1985) Occurrence of Three Cases of Carcinoma in Individuals with Crohn’s Disease Treated with Metronidazole. American Journal of Gastroenterology, 80, 978-982.
[16] Altaee, M.Y., Johnson, P.J., Farrant, J.M. and Williams, R. (1991) Etiologic and Clinical Characteristics of Peripheral and Hilar Cholangiocarcinoma. Cancer, 68, 2051-2055. http://dx.doi.org/10.1002/1097-0142(19911101)68:9<2051::AID-CNCR2820680934>3.0.CO;2-M
[17] Choi, P.M., Nugent, F.W., Zelig, M.P., Munson, J.L. and Schoetz Jr., D.J. (1994) Cholangiocarcinoma and Crohn’s Disease. Digestive Diseases and Sciences, 39, 667-670. http://dx.doi.org/10.1007/BF02088359
[18] Bragazzi, M.C., Cardinale, V., Carpino, G., Venere, R., Semeraro, R., Gentile, R., Gaudio, E. and Alvaro, D. (2012) Cholangiocarcinoma: Epidemiology and Risk Factors. Translational Gastrointestinal Cancer, 1, 21-32.
[19] Blechacz, B., Komuta, M., Roskams, T., Gores, G.J., et al. (2011) Clinical Diagnosis and Staging of Cholangiocarcinoma. Nature Reviews Gastroenterology & Hepatology, 8, 512-522.
http://dx.doi.org/10.1038/nrgastro.2011.131
[20] Patel, T. (2011) Cholangiocarcinoma—Controversies and Challenges. Nature Reviews Gastroenterology & Hepatology, 8, 189-200. http://dx.doi.org/10.1038/nrgastro.2011.20
[21] Carriaga, M.T. and Henson, D.E. (1995) Liver, Gallbladder, Extrahepatic Bile Ducts, and Pancreas. Cancer, 75, 171-190.
http://dx.doi.org/10.1002/1097-0142(19950101)75:1+<171::AID-CNCR2820751306>3.0.CO;2-2
[22] Shaib, Y.H. and El-Serag, H.B. (2004) The Epidemiology of Cholangiocarcinoma. Seminars in Liver Disease, 24, 115-125. http://dx.doi.org/10.1055/s-2004-828889
[23] Schnitzler, F., Fidder, H., Ferrante, M., Noman, M., Arijs, I., Van Assche, G., Hoffman, I., Van Steen, K., Vermeire, S. and Rutgeerts, P. (2009) Long-Term Outcome of Treatment with Infliximab in 614 Patients with Crohn’s Disease: Results from a Single-Centre Cohort. Gut, 58, 492-500.
http://dx.doi.org/10.1136/gut.2008.155812
[24] O’Donnell, S., Murphy, S., Anwar, M.M., O’Sullivan, M., Breslin, N., O’Connor, H.J., Ryan, B.M. and O’Morain, C.A. (2011) Safety of Infliximab in 10 Years of Clinical Practice. European Journal of Gastroenterology & Hepatology, 23, 603-606. http://dx.doi.org/10.1097/MEG.0b013e3283479125
[25] Hudesman, D., Lichtiger, S. and Sands, B. (2013) Risk of Extraintestinal Solid Cancer with Anti-TNF Therapy in Adults with Inflammatory Bowel Disease: Review of the Literature. Inflammatory Bowel Diseases, 19, 644-649. http://dx.doi.org/10.1097/MIB.0b013e318280ebbd
[26] Lust, M. and Travis, S. (2009) Is Anti-TNF Therapy Always Prohibited in Patients with Inflammatory Bowel Disease and Previous Malignancy? Practical Gastroenterology. Inflammatory Bowel Disease.
[27] Rojas-Feria, M., Castro, M., Suárez, E., Ampuero, J. and Romero-Gómez, M. (2013) Hepatobiliary Manifestations in Inflammatory Bowel Disease: The Gut, the Drugs and the Liver. World Journal of Gastroenterology, 19, 7327-7340. http://dx.doi.org/10.3748/wjg.v19.i42.7327
[28] Pedersen, N., Duricova, D., Elkjaer, M., Gamborg, M., Munkholm, P. and Jess, T. (2010) Risk of Extra-Intestinal Cancer in Inflammatory Bowel Disease: Meta-Analysis of Population-Based Cohort Studies. American Journal of Gastroenterology, 105, 1480-1487. http://dx.doi.org/10.1038/ajg.2009.760
[29] Erichsen, R., Jepsen, P., Vilstrup, H., Ekbom, A. and S?rensen, H.T. (2009) Incidence and Prognosis of Cholangiocarcinoma in Danish Patients with and without Inflammatory Bowel Disease: A National Cohort Study, 1978-2003. European Journal of Epidemiology, 24, 513-520. http://dx.doi.org/10.1007/s10654-009-9365-4
[30] Biancone, L., Orlando, A., Kohn, A., Colombo, E., Sostegni, R., Angelucci, E., Rizzello, F., Castiglione, F., Benazzato, L., Papi, C., Meucci, G., Riegler, G., Petruzziello, C., Mocciaro, F., Geremia, A., Calabrese, E., Cottone, M. and Pallone, F. (2006) Infliximab and Newly Diagnosed Neoplasia in Crohn’s Disease: A Multicentre Matched Pair Study. Gut, 55, 228-233. http://dx.doi.org/10.1136/gut.2005.075937
[31] Berman, M.D., Falchuk, K.R. and Trey, C. (1980) Carcinoma of the Biliary Tree Complicating Crohn’s Disease. Digestive Diseases and Sciences, 25, 795-797. http://dx.doi.org/10.1007/BF01345302
[32] Krause, J.R., Ayuyang, H.Q. and Ellis, L.D. (1985) Occurrence of Three Cases of Carcinoma in Individuals with Crohn’s Disease Treated with Metronidazole. American Journal of Gastroenterology, 80, 978-982.
[33] Altaee, M.Y., Johnson, P.J., Farrant, J.M. and Williams, R. (1991) Etiologic and Clinical Characteristics of Peripheral and Hilar Cholangiocarcinoma. Cancer, 68, 2051-2055. http://dx.doi.org/10.1002/1097-0142(19911101)68:9<2051::AID-CNCR2820680934>3.0.CO;2-M
[34] Choi, P.M., Nugent, F.W., Zelig, M.P., Munson, J.L. and Schoetz Jr., D.J. (1994) Cholangiocarcinoma and Crohn’s Disease. Digestive Diseases and Sciences, 39, 667-670. http://dx.doi.org/10.1007/BF02088359  eww141229lx
标签：

评论

发表评论

此博客中的热门博文

Does Immigration Promote the Investment of the Monopolistic Firm?

In the present paper, we examine the effect of increasing uncertainty of immigrants’ growth on the optimal timing of investment of a firm that has a monopolistic power over the labor market. It is revealed that when the uncertainty of immigrants’ growth is more than a threshold level, increasing uncertainty of immigrants’ growth accelerates the optimal timing of firms’ investment and enhances the economic growth, even if the uncertainty of immigrants’ growth is formulated by the geometric Brownian motion, which is in sharp contrast to the standard result that an increase in the uncertainty postpones the optimal timing. With an increase in the immigrants over the past ten years, workforces in the host countries have been growing significantly to the extent that the immigrants represent 70% of the increase in the workforce in Europe, and 47% in the United States as OECD indicates. In the present paper, we attempted to investigate the effect of increased uncertainty caused by the growi...
发表评论
阅读全文

Education Policy Implementation: A Mechanism for Enhancing Primary Education Development in Zanzibar

Education is one of the fundamental rights of individuals; therefore, the government of a country needs to develop and strengthen educational policy and quality as well as to ensure that everyone has equal access to basic education. The improvement of access and quality of education in the world is becoming as an essential factor in development, whereas the basic education (primary school), is acknowledged as a foundation of the higher educational development for every country. To fulfill this goal, governments introduce several policies and procedures; however, it requires some reforms and participation from the politician, policymakers, and other stakeholders to re-examine educational policy so that it can lead to multiplication and betterment of the reforms. Educational reforms actually focus on accountability. A positive educational development and reform is very challenging and needs more effort and strategy on how to use and utilize the resources effectively as such it can achie...
发表评论
阅读全文